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Abstract: This short review tells the story of how Reversed Chloroquine drugs (RCQs) were developed. These are hybrid 
molecules, made by combining the quinoline nucleus from chloroquine (CQ) with moieties which are designed to inhibit 
efflux via known transporters in the membrane of the digestive vacuole of the malaria parasite. The resulting RCQ drugs 
can have potencies exceeding that of CQ, while at the same time having physical chemical characteristics that may make 
them favorable as partner drugs in combination therapies. The need for such novel antimalarial drugs will continue for the 
foreseeable future. 
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INTRODUCTION 
  Chloroquine (CQ) was a truly remarkable drug, and the 
standard of care for malaria over about half a century, begin-
ning in the late 1940s. Speaking about the discovery of CQ 
in a Review Lecture published in 1963, G. Robert Coatney 
stated [1], “Results since 1946 have made it the drug of 
choice for malaria the world over. It was the only antimalar-
ial used by our Armed Forces and most of the Allied Forces 
in Korea. It has since been employed by most of the Free 
World Forces when deployed in malarious areas and is the 
drug of choice in the world-wide malaria eradication pro-
gram under the World Health Organization.” 
  Of course, that worldwide malaria eradication program 
did not succeed, and upon its abandonment the situation re-
garding malaria grew worse. The emergence and subsequent 
spread of drug resistance in malaria had made the (otherwise 
favored) malaria drug CQ ineffective throughout most of the 
world [2]. Combination therapies [3, 4] have now become 
the standard of care for malaria chemotherapy, though cur-
rently available combinations lack CQ’s simplicity & low 
cost. Because malaria will doubtless continue to evolve re-
sistance even to the newest cures [5, 6], there is, and will be 
an ongoing need for a development pipeline of effective 
drugs until eradication of the disease might become a reality. 
  In response to this challenging situation, we embarked 
upon a hybrid-drug approach to overcoming malaria’s drug 
resistance. Chemosensitizers, or reversal agents (RAs), are 
molecules that reverse resistance to a drug. In the context of 
this review, the RA is generally an efflux mechanism inhibi-
tor. RAs for CQ turn the susceptibility of CQ-resistant 
strains back toward that of CQ-sensitive strains [7-11], 
mainly by inhibiting the transporter of CQ from the digestive 
vacuole (DV) – P. falciparum chloroquine-resistance trans-
porter (PfCRT) [12]. We originally hypothesized and 
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showed that CQ-resistance could be reversed by covalently 
bonding CQ to a RA, producing a single molecule that we 
term a ‘reversed-CQ’ (RCQ) compound [13]; this is illus-
trated in Fig. (1). An RCQ compound has a significant ad-
vantage over a cocktail of CQ and RA because CQ accumu-
lates strongly in the parasite’s DV, so the linked RA entity 
accumulates to a much higher concentration than an unlinked 
RA. The drug:RA ratio is, by definition, 1:1. We have dem-
onstrated the feasibility of this approach by making several 
dozens of these compounds, and shown that the design is 
robust and flexible [13-15]. We have generated a large num-
ber of potent and novel RCQ compounds that are very effec-
tive against both CQ-sensitive and CQ-resistant strains at 
concentrations far lower than CQ or other similar drugs. In 
vitro cytotoxicity results for these drugs are favorable [14, 
15]. In fact, with the better RCQ drugs we have not observed 
any adverse effects in mice when the drugs are administered 
orally with an amount well over an order of magnitude above 
the in vivo ED50 values, and well above the fatal CQ dose. 
  What follows is a short story about how the RCQ mole-
cules have developed in our laboratory, and a brief descrip-
tion of a few molecule classes that are closely related to the 
RCQ design. The reader can refer to other publications for 
reviews covering fundamentals of malaria’s CQ-resistance 
[16], the discovery and development of resistance reversal 
drugs [10, 17], hybrid drugs for malaria [18], as well as hy-
brid drugs generally [19, 20], in addition to a recent review 
covering the need for new malaria drugs [21]. 
THE “TARGET”: PfCRT 
  A protein localized to the membrane defining the diges-
tive vacuole (DV) of P. falciparum was discovered by the 
Wellems group at NIH to have mutations that are correlated 
to CQ-resistance [12]. Since the function of this protein was 
not known, it was designated as the, “P. falciparum Chloro-
quine Resistance Transporter,” or PfCRT. Although there 
were multiple mutations found within the locus of the pfcrt 
gene, a key mutation for CQ-resistance was K76T. Most 
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importantly, incorporation of this mutation into a CQ-
sensitive strain induced the CQ-resistance trait. This, and 
several quickly following papers, e.g., [22-25] established 
the importance of this point mutation in P. falciparum CQ-
resistance, although other mutations and probably other 
transporters are known to modulate the trait [16, 22, 25-27]. 
  The structure of PfCRT has been predicted to contain 10 
transmembrane helices, with the N- and C- termini extending 
into the parasite’s cytoplasm, away from the DV [12]. The 
K76T location is near at the proposed DV-end of the   
N-terminal (first) transmembrane helix, and so could interact 
electrostatically with drugs like CQ, which exists as the dica-
tion when in the acidic DV; the loss of the positively-
charged lysine residue could then form the basis for resis-
tance by reducing this unfavorable interaction such that the 
drug then can bind and be transported. In any event, the 
thermodynamics involved in the transport process are not 
simple, as recently reviewed [27]. 
THE FIRST RCQ MOLECULE 
  The fundamental design of a reversed drug molecule is a 
hybridization of the original drug with a reversal agent 
(chemosentizer) that can inhibit the resistance mechanism, in 
this case the export of the drug by an efflux mechanism. For 
our initial RCQ drug, we chose a reversal agent moiety that 
was known to produce a buildup of CQ (pKa ~ 8.1 & 10.2 
[28]) within the parasite (and so presumably in the DV; pH ~ 
5 [28]). Such molecules, including verapamil (VP), are often 
thought of by their activities as calcium channel blockers. 
Although VP was the usual reference for a CQ-resistance 
reversal agent, it is somewhat complex from a chemical per-
spective. However a simpler choice, imipramine (pKa ~ 9.5 
[29]), was also known to be a potent RA [11, 30-32], and is 
achiral, unlike VP and many other reversal agents known to 
act against CQ-resistance. The commercial availability of 
desimipramine led to a simple synthesis for the molecule, 1, 
also achiral and first published in 2006 [13]. The structure 
and synthetic route are shown in Fig. (2). This molecule, to 
our knowledge, was the first reported hybrid drug that inten-
tionally incorporated a chemical-efflux inhibitor coupled to a 
drug molecule. When tested in vitro against both a CQ-
sensitive  P. falciparum strain (D6) and against a CQ-
resistant strain (Dd2), using the SYBR Green I-based fluo-
rescence assay [33], it was found to be more potent than CQ 
against either strain, even the CQ-sensitive strain. However, 
RCQ molecule 1 has a very high estimated clogP of nearly 9, 
as well as a clogD of 4.2 at pH 7.4 (Marvin 5.5.0.0, 2011, 
ChemAxon (http://www.chemaxon.com) was used for this 
calculation), and so was not expected to be a practical drug 
itself. Nonetheless, we evaluated the in vivo potential of the 
RCQ drugs in a small mouse trial using P. chabaudi, and 
found that 1 had >99% suppressive activity at 64 mg/kg/day 
in a standard 4-day suppressive test. It is important, however, 
to remember that 1 was a prototype molecule, assembled to 
test the principle without being optimized. We then returned 
to the principles of the RA pharmacophore to begin the op-
timization process. 
SECOND-GENERATION RCQ MOLECULES 
  The structural essentials for the CQ-resistance reversing 
RA molecules identified by Bhattacharjee et al. in 2002 [34] 
included, “Two aromatic hydrophobic sites and a hydrogen 
bond acceptor site, preferably at a side chain nitrogen atom. 
We took this conclusion, based on a modeling / calculation 
approach based on a training set of 17 compounds, as license 
to open up the RA structure to modifications in a guided way 
that would remove the tricyclic nature of the imipramine-
based RA end of molecule 1. This might reduce or eliminate 
any central neural system (CNS) activity of the resultant 
drugs. In addition, there were the questions of water-
solubility and oral availability of the drug to address. 
  We began to evaluate the structural requirements for an 
RCQ drug by examining the limits to which one could prac-
tically vary the “linker” between the quinoline and the RA’s 
side-chain nitrogen, as well as between that nitrogen and the 
RA aromatic rings [14]. We found little differences between 
RCQ molecules that had between 2 and 4 carbons in the 
linker between the quinoline and the RA’s side-chain nitro-
gen, and significant changes could be made to the RA struc-
tures themselves. A few examples are shown in Table 1. The 
length of the chain between the nitrogen and the 2 aromatic 
groups was varied between 2 and 4 carbons (and changed to 
a piperazinyl ring) with little change in activity, as well as 
incorporating a carbonyl (but not converting the central ni-
trogen into an amide). The aromatic rings were converted 
from phenyls to benzyls, with little change in activity. A 
recent paper addresses the ability of this moiety to act spe-
cifically as an inhibitor of mutated PfCRT [35]. Two other 
points that arose from this structure-activity relationship 
(SAR) work were that having a proton on the quinoline’s 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). The original concept leading to RCQ drugs. Note the chiral center in CQ that we eliminate in a RCQ drug. 
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Fig. (2). The synthesis and structure of prototype RCQ molecule, 1 [13]. The hydrogen-bond accepting nitrogen is indicated with an ar-
row, and the reversal agent aromatic groups are circled; the RA moiety will be shown in bold bonds throughout. In the structure of 1, the qui-
noline and linker are contained in the line-box, and the RA moiety is in the dotted box. 
 
Table 1.  Selected RCQ Activities against P. falciparum [14] 
IC50 
b (nM) 
Compound ClogP
 a 
D6 
(CQ
S) 
Dd2 
(CQ
R) 
IC50 Ratio 
Dd2/D6 
Cytotoxicity 
c 
(nM) 
CQ 
 
5.1 7  102 15 12000 
1 
 
8.9 3 5  1.7  700 
2 
 
3.5 1.6  1.8  1.1  6500 
3 
 
7.5 1.3  1.3  1.0  1100 
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(Table 1) contd…. 
IC50 
b (nM) 
Compound ClogP
 a 
D6 
(CQ
S) 
Dd2 
(CQ
R) 
IC50 Ratio 
Dd2/D6 
Cytotoxicity 
c 
(nM) 
4 
 
7.0 10  16  1.6  2200 
5 
 
7.3 7  16 2.3  N.D. 
6 
 
7.3 2 6  3.0  N.D. 
7 
 
7.6 23  34  1.5  700 
8 
 
7.4 8  11 1.4 1300 
a Evaluated using ChemDraw software. 
b Averages of at least 3 runs (± 15%). The uncertainties are estimated based on weighing uncertainties for the various compounds (which are free-bases and often oils), as well as on 
variability between determinations that were performed on different weeks. 
c Cytotoxicities are against mouse spleen lymphocytes. These values are estimated to be ±50%, based on weighing uncertainties for the various compounds (which are free-bases and 
often oils), as well as on variability between determinations that were performed on different weeks. N.D.: not determined. 
 
4-amino was beneficial, and that having two RA groups was 
not a strong advantage. So there was great breadth in scope 
found for RCQ design, and considerations such as pharma-
cology and cost could then be addressed with few con-
straints. In fact, the latitude for RCQ design appeared to be 
much greater than for developing a ‘simple’ RA. 
  This conclusion underscores the point that there are fun-
damental differences in the requirements for the design of an 
effective RA drug, as opposed to RCQ drugs. First, the RCQ 
molecule’s fundamental activity must be antimalarial activ-
ity. The functional requirement of a RA molecule is the abil-
ity to inhibit efflux of CQ in a malaria strain; the function of 
a RA moiety in a RCQ drug is to enhance buildup of the 
drug in the DV (presumably by decreasing efflux of itself). 
This latter property does not necessarily require that it be 
able to inhibit efflux of CQ. In fact, it may be that the best 
RCQ drugs may not interact with an efflux effector such as 
PfCRT at all: RCQ drugs could bind other transporters in the 
DV, or they could simply have lower binding to all such 
transporters. This is because binding is the first step in trans-
port, so that reduced binding could lead to a higher RCQ 
drug concentration in the DV, even though it would be a less 
effective RA for CQ export. Therefore, it may be easier to 
design an optimized RCQ drug RA than it would be to de-
sign the corresponding RA moiety. 
AN IMPROVED RCQ MOLECULE 
  We continued the SAR work, taking advantage of the 
above-referenced flexibility to find a molecule, 2, that has 
great water solubility, has good in vitro antimalarial activity 
against a variety of CQ-resistant and CQ-sensitive P. falci-
parum strains, and is orally curative in mice. Its IC50 values 404    Current Topics in Medicinal Chemistry, 2012, Vol. 12, No. 5  David H. Peyton 
against D6, Dd2, and 7G8 were about 1, 2, and 2 nM, as 
compared to CQ values of 7, 102, and 106 nM. Having a 
clogP value of about 3.5 (CQ has a value of about 5), 2 was 
anticipated to have good water solubility, especially as a salt 
formulation (e.g., chloride or phosphate). Low cytotoxicity 
values (in our studies, to mouse spleen lymphocytes), and 
the resulting favorable therapeutic index values were found 
for many RCQ molecules. For example, the therapeutic in-
dex values for CQ and 2 were found to be about 120 and 
4000, respectively (ratio of IC50 for mouse spleen lympho-
cytes / P. falciparum strain Dd2). In vivo work in mice found 
that 2 could cure mice of a P. berghei infection at an equi-
molar dose to 30 mg/kg/day for CQ. Remarkably, while CQ 
kills at < 200 mg/kg in mice, we could orally dose 2 to > 400 
mg/kg in mice without evident adverse effects for at least 3 
days (unpublished). 
MECHANISM(S) OF ACTION 
  While the full story about the mode(s) of action for CQ is 
not certain, it has been widely assumed to involve interaction 
with heme, a byproduct of hemoglobin digestion by the 
Plasmodium parasite. We therefore evaluated the binding of 
heme by both CQ and 1 using UV-vis spectroscopy. A bind-
ing stoichiometry of one drug molecule to one heme μ-oxo 
dimer was assumed. At pH 5.7, near the DV pH, the meas-
ured binding constant (3  10
5 M
-1) was found to be the same 
as measured for CQ (3  10
5 M
-1). The measured binding 
constant at pH 7 (also 3  10
5 M
-1) was also found to be 
comparable to that which we measured for CQ (1  10
6 M
-1) 
under the same conditions. The conclusion is that the RA 
portion of 1 does not appear to affect the CQ-like binding to 
heme. This conclusion has been supported by a recent study 
[36]. Compound 2 Fig. (3) also proved to be an avid mole-
cule for the heme μ-oxo dimer, and was about 3-fold more 
efficient at inhibiting -hematin formation as Compound 1. 
This may indicate that the high potencies of the drugs is a 
combination of both enhanced accumulation and enhanced 
interaction with heme, both relative to CQ. We also tested 
the ability to accumulate in P. falciparum-parasitized red 
cells. In this test, compound 1 did, in fact, accumulate to a 
stronger degree than did CQ, as measured by the drop of 
drug concentration in the surrounding medium. Light micro-
scopic analysis of surviving parasites in high concentrations 
of 1 showed a strongly swelled DV, as well as very little 
apparent hemozoin crystals. CQ under the same conditions 
showed the same qualitative effects, but to a lesser extent. 
All this is consistent with an inhibition of hemozoin forma-
tion mechanism for the RCQ molecules, in analogy with the 
accepted mechanism of CQ, except that the RCQ molecule is 
generally more potent across the range of effects. 
  We found that the RCQ drugs’ effectiveness is not due to 
varying the length of the linker between the quinoline and 
the central nitrogen; this result is important because others 
have found that such changes alone can overcome CQ-
resistance. Thus, we synthesized a compound 3 Fig. (3), 
which was found to have better antimalarial activity than 
CQ, and in combination with the work cited above, we con-
cluded that the ability of the RCQ molecules to overcome 
CQ-resistance by the addition of a RA head group to the 4-
aminoquinoline ring is, in fact, independent of the chain 
length between them, at least if the chain length is between 2 
and 4 carbons. 
  The question of whether the RCQ molecules actually 
inhibit PfCRT’s ability to export CQ in strains which are 
CQ-resistant may best be evaluated by measurement systems 
such as implemented by Martin and Kirk [28, 35]. In fact, 
molecules such as 1 and 2 do inhibit this ability to inhibit CQ 
transport by PfCRT
76T (unpublished data). 
RELATED MOLECULES 
 October et al. used the chemistry of 3,4-
Dihydropyrimidin-2(1H)-ones to construct RCQ molecules 
[37]; Fig. (4). Although such molecules lack the protonatable 
nitrogen of the classical pharmacophore, this structure did 
exhibit excellent potency against CQ-sensitive and CQ-
resistant malaria strains. Another set of molecules, linking 
astemizole to the CQ quinoline end likewise proved hopeful 
[38]. Substitution of adamantyl groups for the phenyls in the 
RA pharmacophore has proved somewhat successful for 
others [39] in overcoming P. falciparum resistance, as well 
in our laboratory (unpublished). Screening led to related 
structures, e.g., [40, 41]. The acridine skeleton has been hy-
bridized to CQ to make related RCQ structures [42]. The 
dibemethin group was appended to quinolines to make re-
lated hybrids [43], based on this group’s ability to inhibit 
PfCRT-mediated efflux of CQ [35], as outlined above. The 
drug candidate ferroquine [44, 45] may owe much of its po-
tency to the ability to accumulate in the DV and not be ex-
ported by mutated PfCRT. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Two additional key RCQ molecules [15]. RCQ drug 2 has good water solubility and oral efficacy, and RCQ 3 has the same linker 
length between the 4-amino group and the next nitrogen as does CQ. Both have high potencies against CQ-sensitive and CQ-resistant P. 
falciparum strains. 
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Compound 19 from October, et al. [37] (left) and Compound 6 from [43] (right).  
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Compound 30 from Kumar, et al. [42] (left) and ferroquine (right). 
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Imipramine (a reversal agent) (left), and piperaquine (center), and a bisquinoline [46], with the RA pharmacophore superimposed on each. 
 
Fig. (4). Examples of other molecules may be viewed as sharing aspects of RCQ drugs.  
 
  Even some older work, eg., bisquinolines; Fig. (4) [46, 
47], including piperaquine [48], make up an interesting set of 
compounds which may be viewed as potential RCQ mole-
cules, especially if nitrogen atoms are used in the segment 
that links the quinolines. The approved drug, piperaquine 
makes an interesting case. Fig. (4) shows the essential ele-
ments of the RA moiety superimposed on both imipramine 
and one end of a piperaquine molecule. In fact, one can al-
most think of CQ itself as a RA pharmacophore, in that the 
molecule can roughly fit the essential structural elements. 
Also, binding to PfCRT, a requisite for transport is a trait 
shared by RA molecules. In fact, PfCRT (mutated or not) 
may be able to transport some or all of the RA molecules, to 
various extents [49]. 
NEXT-GENERATION RCQ MOLECULES 
  Future efforts in designing RCQ molecules will be aimed 
in two directions. First, we are attempting to vary the RA 
end to a greater extent, with the idea that it may not be nec-
essary to retain strong binding to PfCRT. The other direction 
will be to vary the substituent pattern on the quinoline ring 
system, as has been done for CQ-like structures by others, 
e.g., [50]. Both of these directions may help to reduce the 
hERG binding which gives rise to the potential cardiotoxic-
ity common to quinoline-based malaria drugs [51]. We al-
ready have some evidence that the effects of changing the 
substituents are not the same as found in CQ and its deriva-
tives. 
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THE ROLE FOR RCQ MOLECULES IN THE 
WORLD-WIDE MALARIA STRATEGY 
  One could ask why would we wish to develop new 4-
aminoquinoline drugs against malaria, especially in the face 
of the failure of CQ? The first reason is that the drugs are 
generally inexpensive to produce, particularly on a large 
scale. The starting materials are not exotic, and the chemistry 
required to assemble the molecules is quite safe and simple 
[13-15]. Second, the RCQ molecules are a fairly strong de-
parture from the side chain of CQ, so that there may be 
minimal cross-resistance to other strains. In fact, we have 
evaluated several “field-isolated” strain clones developed 
from infected patients, and found no significant resistance to 
any of several of the RCQ drugs. Third, the design is exceed-
ingly flexible. This is important because if resistance does 
emerge against one drug, then it is possible that a next-
generation RCQ could take its place. Forth, the physical-
chemical properties can be chosen such that its pharmacoki-
netic parameters would be a good match for another drug in 
combination therapy, and such ability could be very useful 
for optimizing drug combinations. Finally, CQ was really a 
very good drug for nearly half a century. If we are successful 
in developing RCQ drugs that are even better in terms of 
efficacy and safety than CQ, then we could use the advan-
tages of quinoline antimalarial drugs in another attempt at 
eradicating the disease. Given the RCQ potencies, it is con-
ceivable to aim for single-dose radical cures that are hoped 
for in an elimination / eradication global strategy [52, 53], 
especially as a part of combination drugs in which the part-
ners are carefully chosen to complement each other’s abili-
ties and properties. 
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ABBREVIATIONS 
CQ =  Chloroquine 
PfCRT =  Plasmodium falciparum chloroquine resis-
tance transporter 
DV =  Digestive  vacuole 
CQ-resistant =  Chloroquine resistant 
CQ-senstive =  Chloroquine  sensitive 
RA =  Reversal  agent 
RCQ =  Reversed  chloroquine  compound 
SAR =  Structure-activity  relationship 
REFERENCES 
[1]  Coatney, G.R. Pitfalls in a discovery, the chronicle of chloroquine. 
The American J.Tropic. Med. Hygiene, 1963, 12,121-128. 
[2] Packard,  R.M.  The Making of a Tropical Disease , A Short History 
of Malaria. Baltimore, Md., Johns Hopkins University Press; 2007. 
[3]  Kumar, A.; Katiyar, S.B.; Agarwal, A.; Chauhan, P.M. Perspective 
in antimalarial chemotherapy. Curr. Med. Chem., 2003, 10,1137-
1150. 
[4]  Dondorp, A.M.; Yeung, S.; White, L.; Nguon, C.; Day, N.P.; 
Socheat, D.; von Seidlein, L. Artemisinin resistance, current status 
and scenarios for containment. Nat. Rev. Microbiol., 2010, 8, 272-
280. 
[5]  Noedl H, Socheat D, Satimai W, Artemisinin-resistant malaria in 
Asia. N. Engl. J. Med., 2009, 361,540-541. 
[6]  Noedl, H. Se, Y.; Schaecher, K.; Smith, B.L.; Socheat, D.; Fukuda, 
M.M. Evidence of artemisinin-resistant malaria in western 
Cambodia. N. Engl. J. Med., 2008, 359,2619-2620. 
[7]  Krogstad, D.J.; Gluzman, I.Y.; Kyle, D.E.; Oduola, A.M.; Martin, 
S.K.; Milhous, W.K.; Schlesinger, P.H. Efflux of chloroquine from 
Plasmodium falciparum, mechanism of chloroquine resistance. 
Science, 1987, 238,1283-1285. 
[8]  Martin, S.K.; Oduola, A.M.; Milhous, W.K. Reversal of 
chloroquine resistance in Plasmodium falciparum by verapamil. 
Science, 1987, 235,899-901. 
[9]  van Schalkwyk, D.A.; Walden, J.C.; Smith, P.J. Reversal of 
chloroquine resistance in Plasmodium falciparum using 
combinations of chemosensitizers. Antimicrob. Agents Chemother., 
2001, 45,3171-3174. 
[10]  van Schalkwyk, D.A.; Egan, T.J. Quinoline-resistance reversing 
agents for the malaria parasite Plasmodium falciparum. Drug 
Resist. Updat, 2006, 9, 211-226. 
[11]  Guan, J.; Kyle, D.E.; Gerena, L.; Zhang, Q.; Milhous, W.K.; Lin, 
A.J. Design, synthesis, and evaluation of new chemosensitizers in 
multi-drug-resistant Plasmodium falciparum. J. Med. Chem., 2002, 
45,2741-2748. 
[12]  Fidock, A.D.; Nomura, T.; Talley, K.A.; Cooper, A.R.; Dzekunov, 
M.S.; Ferdig, T.M.; Ursos, M.L.; Sidhu, A.B.; Naude, B.; Deitsch, 
W.K.; Su, X.Z.; Wootton, J.C.; Roepe, P.D.; Wellems, T.E. 
Mutations in the P. falciparum digestive vacuole transmembrane 
protein PfCRT and evidence for their role in chloroquine 
resistance. Mol. Cell, 2000, 6,861-871. 
[13]  Burgess, S.J.; Selzer, A.; Kelly, J.X.; Smilkstein, M.J.; Riscoe, 
M.K.; Peyton, D.H.; A chloroquine-like molecule designed to 
reverse resistance in Plasmodium falciparum. J. Med. Chem., 2006, 
49,5623-5625. 
[14]  Andrews, S.; Burgess, S.J.; Skaalrud, D.; Kelly, J.X.; Peyton, D.H. 
Reversal agent and linker variants of reversed chloroquines, 
activities against Plasmodium falciparum.  J. Med. Chem., 2010, 
53,916-919. 
[15]  Burgess, S.J.; Kelly, J.X.; Shomloo, S.; Wittlin, S.; Brun, R.; 
Liebmann, K.; Peyton, D.H. Synthesis, structure-activity 
relationship, and mode-of-action studies of antimalarial reversed 
chloroquine compounds. J. Med. Chem., 2010, 53,6477-6489. 
[16]  Roepe, P.D. Molecular and physiologic basis of quinoline drug 
resistance in Plasmodium falciparum malaria. Future Microbiol., 
2009, 4,441-455. 
[17]  Henry, M.; Alibert, S.; Orlandi-Pradines, E.; Bogreau, H.; Fusai, 
T.; Rogier, C.; Barbe, J.; Pradines, B. Chloroquine resistance 
reversal agents as promising antimalarial drugs. Curr. Drug 
Targets, 2006, 7, 935-948. 
[18]  Walsh, J.J.; Bell, A. Hybrid drugs for malaria. Curr. Pharm. Des., 
2009, 15,2970-2985. 
[19]  Morphy, R.; Kay, C.; Rankovic, Z.; From magic bullets to designed 
multiple ligands. Drug Discov. Today, 2004, 9,641-651. 
[20]  Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging 
drug discovery paradigm. J. Med. Chem., 2005, 48,6523-6543. 
[21]  Grimberg, B.T.; Mehlotra, R.K. Expanding the antimalarial drug 
arsenal-now, but how? Pharmaceuticals, 2011, 4, 681-712. RCQ Drugs to Overcome Resistance  Current Topics in Medicinal Chemistry, 2012, Vol. 12, No. 5    407 
[22]  Cooper, R.A.; Ferdig, M.T.; Su, X.Z.; Ursos, L.M.; Mu, J.; 
Nomura, T.; Fujioka, H.; Fidock, D.A.; Roepe, P.D.; Wellems, T.E. 
Alternative mutations at position 76 of the vacuolar transmembrane 
protein PfCRT are associated with chloroquine resistance and 
unique stereospecific quinine and quinidine responses in 
Plasmodium falciparum. Mol. Pharmacol., 2002, 61,35-42. 
[23]  Mehlotra, R.K.; Fujioka, H.; Roepe, P.D.; Janneh, O.; Ursos, L.M.; 
Jacobs-Lorena, V.; McNamara, D.T.; Bockarie, M.J.; Kazura, J.W.; 
Kyle, D.E.; Fidock, D.A.; Zimmerman, P.A. Evolution of a unique 
Plasmodium falciparum chloroquine-resistance phenotype in 
association with pfcrt polymorphism in Papua New Guinea and 
South America. Proc. Natl. Acad. Sci. USA, 2001, 98,12689-12694. 
[24]  Sidhu, A.B.; Verdier-Pinard, D.; Fidock, D.A. Chloroquine 
resistance in Plasmodium falciparum malaria parasites conferred by 
pfcrt mutations. Science, 2002, 298, 210-213. 
[25]  Mu, J.; Ferdig, M.T.; Feng, X.; Joy, D.A.; Duan, J.; Furuya, T.; 
Subramanian, G.; Aravind, L.; Cooper, R.A.; Wootton, J.C.; Xiong, 
M.; Su, X.Z. Multiple transporters associated with malaria parasite 
responses to chloroquine and quinine. Mol. Microbiol., 2003, 49, 
977-989. 
[26]  Biagini, G.A.; Fidock, D.A.; Bray, P.G.; Ward, S.A. Mutations 
conferring drug resistance in malaria parasite drug transporters 
Pgh1 and PfCRT do not affect steady-state vacuolar Ca2+. 
Antimicrob. Agents Chemother., 2005, 49, 4807-4808. 
[27]  Roepe, P.D. PfCRT-mediated drug transport in malarial parasites. 
Biochemistry, 2010, 50, 168-171. 
[28]  Martin, R.E.; Marchetti, R.V.; Cowan, A.I.; Howitt, S.M.; Broer, 
S.; Kirk, K. Chloroquine transport via the malaria parasite's 
chloroquine resistance transporter. Science, 2009, 325,1680-1682. 
[29]  Martindale, W.; Reynolds, .JE.F. Royal pharmaceutical society of 
great britain. Dept. Pharmaceutical Sciences. The extra 
pharmacopoeia. 30
th ed., London, Pharmaceutical Press; 1993. 
[30]  Adam, M.E.; El Fatih, E.; Karim, A.Y.; Ibrahim, K.E.E.; Berger, 
B.J.; Wiese, M.; Babiker, H.A. Imipramine induced complete 
reversal of chloroquine resistance in Plasmodium falciparum 
infections in Sudan. Saudi Pharm. J., 2004, 12,130-135. 
[31]  Bhattacharjee, A.K.; Kyle, D.E.; Vennerstrom, J.L. Structural 
analysis of chloroquine resistance reversal by imipramine analogs. 
Antimicrob. Agents Chemother., 2001, 45,2655-2657. 
[32]  Miki, A.; Tanabe, K.; Nakayama, T.; Kiryon, C.; Ohsawa, K.; 
Plasmodium chabaudi, association of reversal of chloroquine 
resistance with increased accumulation of chloroquine in resistant 
parasites. Exp. Parasitol., 1992, 74,134-142. 
[33]  Smilkstein, M.; Sriwilaijaroen, N.; Kelly, J.X.; Wilairat, P.; Riscoe, 
M. Simple and inexpensive fluorescence-based technique for high-
throughput antimalarial drug screening. Antimicrob. Agents 
Chemother., 2004, 48,1803-1806. 
[34]  Bhattacharjee, A.K.; Kyle, D.E.; Vennerstrom, J.L.; Milhous, W.K. 
A 3D QSAR pharmacophore model and quantum chemical 
structure--activity analysis of chloroquine(CQ)-resistance reversal. 
J. Chem. Inf. Comput. Sci., 2002, 42,1212-1220. 
[35]  Zishiri, V.K.; Hunter, R.; Smith, P.J.; Taylor, D.; Summers, R.; 
Kirk, K.; Martin, R.E.; Egan, T.J. A series of structurally simple 
chloroquine chemosensitizing dibemethin derivatives that inhibit 
chloroquine transport by PfCRT. Eur. J. Med. Chem., 2011, 
46,1729-1742. 
[36]  Otelo, V.A.; Sant'Ana, A.C.; de Faria, D.L.; Menezes, C.M. 
Molecular modeling and UV-vis spectroscopic studies on the 
mechanism of action of reversed chloroquine (RCQ). Bioorg. Med. 
Chem. Lett., 2011, 21,250-254. 
[37]  October, N.; Watermeyer, N.D.; Yardley, V.; Egan, T.J.; Ncokazi, 
K.; Chibale, K. Reversed chloroquines based on the 3,4-
dihydropyrimidin-2(1H)-one scaffold, synthesis and evaluation for 
antimalarial, beta-haematin inhibition, and cytotoxic activity. 
ChemMedChem, 2008, 3,1649-1653. 
[38]  Musonda, C.C.; Whitlock, G.A.; Witty, M.J.; Brun, R.; Kaiser, M. 
Chloroquine-astemizole hybrids with potent in vitro and in vivo 
antiplasmodial activity. Bioorg. Med. Chem. Lett., 2009, 19,481-
484. 
[39]  Solaja, B.A.; Opsenica, D.; Smith, K.S.; Milhous, W.K.; Terzic, N.; 
Opsenica, I.; Burnett, J.C.; Nuss, J.; Gussio, R.; Bavari, S. Novel 4-
aminoquinolines active against chloroquine-resistant and sensitive 
P. falciparum strains that also inhibit botulinum serotype A. J. Med. 
Chem., 2008, 51,4388-4391. 
[40]  Ray, S.; Madrid, P.B.; Catz, P.; LeValley, S.E.; Furniss, M.J.; 
Rausch, L.L.; Guy, R.K.; DeRisi, J.L.; Iyer, L.V.; Green, C.E.; 
Mirsalis, J.C. Development of a new generation of 4-
aminoquinoline antimalarial compounds using predictive 
pharmacokinetic and toxicology models. J. Med. Chem., 2010, 53, 
3685-3695. 
[41]  Madrid, P.B.; Wilson, N.T.; DeRisi, J.L.; Guy, R.K. Parallel 
synthesis and antimalarial screening of a 4-aminoquinoline library. 
J. Comb. Chem., 2004, 6,437-442. 
[42]  Kumar, A.; Srivastava, K.; Kumar, S.R.; Puri, S.K.; Chauhan, P.M. 
Synthesis of new 4-aminoquinolines and quinoline-acridine hybrids 
as antimalarial agents. Bioorg. Med. Chem. Lett., 2010, 20,7059-
7063. 
[43]  Zishiri, V.K.; Joshi, M.C.; Hunter, R.; Chibale, K.; Smith, P.J.; 
Summers, R.L.; Martin, R.E,; Egan, T.J, Quinoline antimalarials 
containing a dibemethin group are active against chloroquinone-
resistant Plasmodium falciparum and inhibit chloroquine transport 
via the P. falciparum chloroquine-resistance transporter (PfCRT). J. 
Med. Chem., 2011, 54, 6956-6968. 
[44]  Dive, D.; Biot, C. Ferrocene conjugates of chloroquine and other 
antimalarials, the development of ferroquine, a new antimalarial. 
ChemMedChem, 2008, 3,383-391. 
[45]  Dubar, F.; Khalife, J.; Brocard, J.; Dive, D.; Biot, C. Ferroquine, an 
ingenious antimalarial drug, thoughts on the mechanism of action. 
Molecules, 2008, 13, 2900-2907. 
[46]  Vennerstrom, J.L.; Ager, A.L. Jr.; Dorn, A.; Andersen, S.L.; 
Gerena, L.; Ridley, R.G.; Milhous, W.K. Bisquinolines. 2. 
Antimalarial N,N-bis(7-chloroquinolin-4-yl)heteroalkanediamines. 
J. Med. Chem., 1998, 41, 4360-4364. 
[47]  Vennerstrom, J.L.; Ellis, W.Y.; Ager, A.L. Jr.; Andersen, S.L.; 
Gerena, L.; Milhous, W.K. Bisquinolines. 1. N,N-bis(7-
chloroquinolin-4-yl)alkanediamines with potential against 
chloroquine-resistant malaria. J. Med. Chem., 1992, 35, 2129-2134. 
[48]  Warhurst, D.C.; Craig, J.C.; Adagu, I.S.; Guy, R.K.; Madrid, P.B.; 
Fivelman, Q.L. Activity of piperaquine and other 4-aminoquinoline 
antiplasmodial drugs against chloroquine-sensitive and resistant 
blood-stages of Plasmodium falciparum. Role of beta-haematin 
inhibition and drug concentration in vacuolar water- and lipid-
phases. Biochem. Pharmacol., 2007, 73,1910-1926. 
[49]  Lehane, A.M.; Kirk, K. Efflux of a range of antimalarial drugs and 
'chloroquine resistance reversers' from the digestive vacuole in 
malaria parasites with mutant PfCRT. Mol. Microbiol.,  2010, 
[Epub ahead of print]. 
[50]  Madrid, P.B.; Sherrill, J.; Liou, A.P.; Weisman, J.L.; Derisi, J.L.; 
Guy, R.K. Synthesis of ring-substituted 4-aminoquinolines and 
evaluation of their antimalarial activities. Bioorg. Med. Chem. Lett., 
2005, 15,1015-1018. 
[51]  White, N.J. Cardiotoxicity of antimalarial drugs. The Lancet 
infectious diseases 2007, 7, 549-558. 
[52]  Alonso, P.; Brown, G.; Arevalo-Herrera, M.; Binka, F.; Chitnis, C.; 
Collins, F.; Doumbo, O.K.; Greenwood, B.; Hall, B.F.; Levine, 
M.M.; Mendis, K.; Newman, R.D.; Plowe, C.V.; Rodríguez, M.H.; 
Sinden, R.; Slutsker, L.; Tanner, M. A research agenda to underpin 
malaria eradication. PLoS Med., 2011, 8(1), e1000406. 
[53]  A research agenda for malaria eradication, drugs. PLoS medicine 
2011, 8(1), e1000402. 
 
 
Received: September 21, 2011  Revised: October 04, 2011  Accepted: October 05, 2011 
 
 